Oligonucleotide Therapeutics Market
完整報告名稱與涵蓋範圍
Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report, By Molecule Type (Antisense Oligonucleotides, Small Interfering RNA, Aptamers), By Therapeutic Area (Rare and Genetic Diseases, Neurology, Cardiovascular and Metabolic Diseases, Oncology, Ophthalmology), By Route of Administration, By Region, and Segment Forecasts, 2026-2035
報告摘要
Oligonucleotide therapeutics are short synthetic nucleic acid drugs, chiefly antisense oligonucleotides, small interfering RNAs, and aptamers, that act on RNA to silence, correct, or modulate gene expression before a protein is ever made. The modality reaches targets undruggable by small molecules or antibodies, and this report covers marketed products, chemistry and delivery platforms, and the therapeutic programs that will shape commercial value through the forecast horizon.
The market's defining transition is from ultra-rare disease toward prevalent chronic conditions. GalNAc conjugation solved hepatocyte delivery so completely that liver-targeted siRNA now supports infrequent subcutaneous dosing regimens attractive in cardiovascular prevention, exemplified by lipid-lowering and hypertension programs in which twice-yearly administration challenges daily oral therapy on adherence grounds. In parallel, splice-switching antisense drugs sustain the neuromuscular franchise built in spinal muscular atrophy and Duchenne muscular dystrophy, and intrathecal delivery keeps expanding neurology applications toward ALS and other neurodegenerative targets. Extrahepatic delivery, particularly to central nervous system, muscle, and adipose tissue, is the key frontier determining which developers capture the next wave, while manufacturing scale-up and cost of goods become strategic as populations widen.
North America anchors revenue through early approvals and specialty reimbursement, Europe adds structured access through managed entry agreements, and Japan holds a notable position in neuromuscular disease. Competition is moderately consolidated around pioneering RNA-focused developers, now joined by large pharmaceutical companies entering through licensing and acquisition.
The InsightAce study delivers revenue forecasts in US$ across molecule type, therapeutic area, route of administration, and regional segments for 2026-2035, with segment trends, competitive landscape review, and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oligonucleotide Therapeutics Market Snapshot
Chapter 4. Global Oligonucleotide Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Molecule Type Estimates & Trend Analysis
5.1. Molecule Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
5.2.1. Antisense Oligonucleotides
5.2.2. Small Interfering RNA
5.2.3. Aptamers
5.2.4. Other Oligonucleotide Modalities
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Rare and Genetic Diseases
6.2.2. Neurology
6.2.3. Cardiovascular and Metabolic Diseases
6.2.4. Oncology
6.2.5. Ophthalmology
6.2.6. Infectious Diseases
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Subcutaneous
7.2.2. Intravenous
7.2.3. Intrathecal
7.2.4. Intravitreal
Chapter 8. Oligonucleotide Therapeutics Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Ionis Pharmaceuticals
10.2. Alnylam Pharmaceuticals
10.3. Biogen
10.4. Sarepta Therapeutics
10.5. Novartis
10.6. Novo Nordisk
10.7. Arrowhead Pharmaceuticals
10.8. Wave Life Sciences
10.9. Silence Therapeutics
10.10. Stoke Therapeutics
10.11. Nippon Shinyaku
10.12. AstraZeneca
圖表清單 List of Tables & Figures
Table 1. Global Oligonucleotide Therapeutics Market Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 1. Global Oligonucleotide Therapeutics Market Segmentation Overview
Table 2. Global Oligonucleotide Therapeutics Market Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Oligonucleotide Therapeutics Market Share by Molecule Type, 2026 & 2035
Table 3. Global Oligonucleotide Therapeutics Market Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. GalNAc Conjugated siRNA Expansion into Cardiovascular Prevention
Table 4. North America Oligonucleotide Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Oligonucleotide Therapeutics Market Share by Therapeutic Area, 2026 & 2035
Table 5. Europe Oligonucleotide Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Extrahepatic Delivery Technology Landscape and Readiness Assessment
Table 6. Asia Pacific Oligonucleotide Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Oligonucleotide Therapeutics Growth Opportunity Analysis
Table 7. Latin America Oligonucleotide Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Approved Oligonucleotide Drug Launch Timeline by Modality
Table 8. Middle East & Africa Oligonucleotide Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Oligonucleotide Therapeutics Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們